With the investment, which includes GLP-1 products, Novo Nordisk said it will increase production capacity across the entire value chain from manufacturing of active pharmaceutical ingredients (API) to packaging, with the vast majority invested in API capacity. The new API facility will be designed as a multi-product facility, with flexibility to accommodate current and future processes.

"The significant investment announced today confirms the importance of utilizing our existing sites, including in Denmark, as cornerstones for not only the growth we see but also to expand as fast as possible by utilizing all the infrastructure, knowledge and competences we already have,” said Henrik Wulff, Novo Nordisk’s executive vice president, Product Supply, Quality & IT. “Our continued investment in global capacity demonstrates the belief we have in our current and future product portfolio and its relevance for people living with serious chronic diseases,” Wulff added.

According to Novo Nordisk, the new API facility will have a footprint of 170,000 m² and will be designed as a multi-product facility with flexibility to accommodate future processes.

Construction projects are scheduled to be finalized gradually from the end of 2025 through 2029. The projects are expected to create 800 new jobs in the facilities when construction is completed, and the facilities are fully equipped.

Earlier this year, Novo Nordisk confirmed that it awaits approvals for a new production site on Funen, Denmark.